Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calsun K2 is a combination nutritional supplement manufactured by Sunlife Pharmaceuticals, an Indian generic pharmaceutical company. It is formulated to support bone health and treat conditions such as osteoporosis, osteomalacia, and calcium or vitamin D deficiencies. The product typically contains calcium citrate malate, cholecalciferol (Vitamin D3), and menaquinone-7 (Vitamin K2-7). Calcium citrate malate provides a highly bioavailable source of elemental calcium for bone mineralization. Cholecalciferol acts as an agonist at the Vitamin D receptor to enhance intestinal calcium absorption. Menaquinone-7 serves as a cofactor for the gamma-carboxylation of osteocalcin, a process that ensures calcium is effectively integrated into the bone matrix and prevents its deposition in soft tissues and arteries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium citrate malate + cholecalciferol + menaquinone-7.